Committed to Excellence in Cancer Research, Education and Patient Care
Inroads
January 2022
Study Links Louisiana's Severe Air Pollution
to Dozens of Cancer Cases Each Year
In addition to estimating Louisiana’s cancer burden from toxic air pollution, the study revealed that poverty has an impact on the relationship between toxic air pollution and cancer incidence. (Source: EPA, Tulane Environmental Law Clinic).
Exposure to high levels of toxic air pollution is estimated to cause 85 cancer cases per year in Louisiana, according to a Tulane University Law School peer-reviewed study published recently in Environmental Research Letters.

The study, conducted by researchers at the Tulane Environmental Law Clinic, compared neighborhood-level cancer incidence data from the Louisiana Tumor Registry with pollution-related cancer risk, as estimated by the Environmental Protection Agency’s National Air Toxics Assessment (NATA). The analysis accounted for geographic differences in other factors that are related to cancer rates, including poverty, race, occupation, obesity, and smoking.

In addition to estimating Louisiana’s cancer burden from toxic air pollution, the study revealed that poverty has an impact on the relationship between toxic air pollution and cancer incidence: the link between the two was apparent in neighborhoods with above-average poverty rates, but was not detected in more affluent communities. 

“We discovered that the relationship between air pollution and neighborhood cancer rates is different in poor versus affluent neighborhoods,” said Kimberly Terrell, PhD, a research scientist at the Tulane Environmental Law Clinic and lead author of the report.

This is the first peer-reviewed study of Louisiana’s cancer burden to account for an interaction between poverty and pollution, Terrell said.

According to the most recent data available from the Centers for Disease Control, Louisiana has the second highest rate of new cancer cases in the nation. While the State of Louisiana funds a cancer prevention program, it does not yet identify pollution exposure as a cancer risk factor.

The study found that among neighborhoods with above-average poverty rates, higher levels of toxic air pollution were strongly linked to higher cancer rates. Louisiana neighborhoods with above-average poverty rates and the most toxic air (i.e. top quartile) had an average annual cancer rate of 502 cases per 100,000 people. This cancer rate was significantly elevated compared to corresponding neighborhoods with low levels of toxic air pollution (bottom quartile; 478.8 cases per 100,000 people) and compared to the overall state average (480.3 cases per 100,000 people). These respective differences account for 91.8 extra cancer cases per year or 85.8 extra cancer cases per year, respectively, after taking into account the population size of the affected neighborhoods (400,788 people).

By contrast, the study did not find a link between air pollution and cancer for more affluent neighborhoods. According to the study authors, these contrasting results could mean that impoverished communities are more susceptible to pollution, or, alternately, that the link between pollution and cancer is harder to detect in affluent communities because affluent people tend to relocate more often, making it harder to connect their pollution exposure with any health outcome.

The study included neighborhoods throughout Louisiana, including the heavily industrialized area between Baton Rouge and New Orleans colloquially known as “Cancer Alley.” While toxic air pollution comes from many different sources, the study focused specifically on cancer risk from “point sources” of toxic air pollution. Point sources in this data set include industrial facilities and power plants, but do not include vehicles, wildfires, airports, homes, or other mobile or diffuse sources of pollution.

The authors accounted for the time lag between pollution exposure and cancer diagnosis by comparing the most recent cancer data available (cases diagnosed between 2008 and 2017) to historical estimates of pollution-related cancer risk, reflecting pollution levels in 2005. Because the study used publicly available data from state and federal agencies, the authors’ findings can be independently reproduced.

Gianna St. Julien, a co-author of the report and a clinical research coordinator at the Tulane Environmental Law Clinic, points to the value of EPA data for cancer prevention.

“Our study connects EPA’s estimates with actual cancer cases in Louisiana. The findings provide evidence that many cancer cases in Louisiana could be prevented by reducing pollution in neighborhoods where EPA estimates a high cancer risk.”

The full study is available here.
Research Scientist,
Tulane Environmental
Law Clinic &
Lead Author of the Study
Clinical Research Coordinator,
Tulane Environmental
Law Clinic &
Co-Author of the Study
Tulane Professor Elected to
National Academy of Inventors
Chenzhong Li, PhD, is a pioneer in the development of biosensors for cancer, neurological diseases and infectious disease diagnosis and treatment. He holds 16 U.S. and international patents with several more pending. (Story by Lance Sumler; photo by Paula Burch Celentano.)
Tulane University professor Chenzhong Li, PhD, has been named a 2021 fellow by the National Academy of Inventors (NAI), an honor that is the highest professional distinction accorded solely to academic inventors.

Li, professor of Biomedical Engineering and Biochemistry at Tulane University School of Medicine and the School of Science and Engineering, leads advances in biochemistry and biomedical engineering research at the Center for Cellular and Molecular Diagnostics. He was one of 164 prolific academic innovators from across the world elected as an NAI Fellow this year.

The NAI Fellows Program highlights academic inventors who have demonstrated a spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on the quality of life, economic development and the welfare of society.

“I am delighted to be selected for a fellowship with the National Academy of Inventors,” Li said. “This is an amazing moment and one of the most important in my professional career. While I have only been a part of the Tulane family for a relatively short amount of time, this recognition gives me the inspiration to improve my work even more in translational research and entrepreneurship education for our faculty and students.”

Li is a pioneer in the development of biosensors for cancer, neurological diseases and infectious disease diagnosis and treatment. He holds 16 U.S. and international patents with several more pending.

Li developed a carbon fiber micro biosensor array — only a few micrometers in size — to find Beta-amyloid proteins, a critical biomarker for Alzheimer’s disease. The needle-like nano biosensor can measure the biomarker at the single neuron level to help better understand Alzheimer’s progression and to fast screen potential drug treatments. He has also invented new technology using nanoparticles to find markers for cancer tumor growth.

Li has also worked as a professional research associate at the startup company Adnavance Technologies, Inc. in Canada where he led an entrepreneurial effort in developing DNA biosensors for the detection of DNA mutations and DNA binding drug screenings.

Since joining Tulane in February 2021, Li has worked with Tony Hu, PhD, the Weatherhead Presidential Chair in Biotechnology Innovation, and his lab to develop advanced diagnostics for infectious diseases including COVID and tuberculosis.

"The caliber of this year's class of NAI Fellows is outstanding. Each of these individuals is highly-regarded in their respective fields," said Dr. Paul R. Sanberg, FNAI, president of the NAI. "The breadth and scope of their discovery is truly staggering. I'm excited not only see their work continue, but also to see their knowledge influence a new era of science, technology, and innovation worldwide."

The 2021 Fellow class hails from 116 research universities and governmental and non-profit research institutes worldwide. They collectively hold over 4,800 issued U.S. patents. Among the new class of Fellows are 33 members of the National Academies of Sciences, Engineering, and Medicine, and three Nobel Laureates, as well as other honors and distinctions. Their collective body of research and entrepreneurship covers a broad range of scientific disciplines involved with technology transfer of their inventions for the benefit of society.

To date, NAI Fellows hold more than 48,000 issued U.S. patents, which have generated over 13,000 licensed technologies and companies, and created more than one million jobs. In addition, over $3 trillion in revenue has been generated based on NAI Fellow discoveries.

The National Academy of Inventors is a member organization comprising U.S. and international universities, and governmental and non-profit research institutes, with over 4,000 individual inventor members and Fellows spanning more than 250 institutions worldwide. It was founded in 2010 to recognize and encourage inventors with patents issued from the United States Patent and Trademark Office, enhance the visibility of academic technology and innovation, encourage the disclosure of intellectual property, educate, and mentor innovative students, and translate the inventions of its members to benefit society.
Krewe de Pink Donates $27.5K to Tulane's Breast Cancer Research Program
Krewe de Pink members gathered in early December 2021 to present their check to support Tulane Cancer Center's Breast Cancer Research Program.
The leadership of Krewe de Pink – a New Orleans-based 501c3 organization dedicated to raising funds for breast cancer research – recently presented Tulane Cancer Center with a check for $27,500, representing the results of their fundraising efforts in 2021.

"These funds are vital to our breast cancer research progress," said Prescott Deininger, PhD, Tulane Cancer Center director. "Unlike the dollars we are awarded through federal research grants, the support provided by Krewe de Pink allows us to pursue leads that would not necessarily be funded otherwise – leads that could very well develop into breakthroughs in how we diagnose and treat breast cancer. Having the freedom and ability to blaze new trails in this way is invaluable to our team and is only possible through the hard work and dedication of every Krewe member."

Proceeds from Krewe de Pink fundraisers benefit the laboratories of Bridgette Collins-Burow, MD, PhD, associate professor of medicine, and Matthew Burow, PhD, associate professor of medicine, whose research teams focus on triple-negative breast cancer.

"Raising these funds under the continued trying circumstances of 2021 was no easy task, and we could not be more grateful to each and every Krewe member for their hard work and dedication," said Burow. "In addition to helping support our research, this kind gift represents an enduring partnership with wonderful people who are dedicated to the same goal we are – a cure for breast cancer."

This latest donation brings Krewe de Pink's cumulative support of Tulane Cancer Center's Breast Cancer Research Program to $152,500.

"An important component of any Cancer Center’s mission is to progress in partnership with the community it serves," said Deininger. "Krewe de Pink helps us to fulfill that goal. Through our partnership – and friendship – with Krewe de Pink members, the momentum of our breast cancer research progress accelerates, and we are deeply grateful."
Congratulations to

Carol Osborne

Krewe de Pink
President Emeritus

who was recently honored by the
as a cancer survivor who has had a
positive impact on the local community!